GsMtx 4

Drug Profile

GsMtx 4

Latest Information Update: 18 Sep 2014

Price : $50

At a glance

  • Originator State University of New York
  • Class Antiarrhythmics; Peptides
  • Mechanism of Action Calcium channel antagonists; Ion channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy
  • No development reported Atrial fibrillation

Most Recent Events

  • 15 Sep 2014 Preclinical trials in Duchenne muscular dystrophy in USA (unspecified route)
  • 15 Sep 2014 Akashi Therapeutics licenses global development and commercialisation rights for GsMtx 4 for Duchenne muscular dystrophy
  • 06 Nov 2002 No development reported - Preclinical for Atrial fibrillation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top